Androgen decline and outcome in castration resistant prostate cancer (mCRPC) patients treated with docetaxel (Doc), prednisone +/- bevacizumab (B)
Publication/Presentation Date
10-2018
Volume
29
Issue
8
First Page
283
Last Page
283
Published In/Presented At
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
Department(s)
Administration and Leadership
Document Type
Article
COinS